Background Chronic kidney disease (CKD) is commonly associated with cachexia, a condition that causes skeletal muscle wasting and an unfavourable prognosis. Although mechanisms leading to cachexia have been intensively studied, the advance of biological knowledges and technologies encourages us to make progress in understanding the pathogenesis of this disorder. Long noncoding RNAs (lncRNAs) are defined as >200 nucleotides RNAs but lack the protein-coding potential. LncRNAs are involved in the pathogenesis of many diseases, but whether they functionally involve in muscle protein loss has not been investigated. Methods We performed lncRNA array and identified an lncRNA, which we named Atrolnc-1, remarkably elevated in atrophying muscles from mice with cachexia. We examined how overexpression or knockdown of Atrolnc-1 could influence muscle protein synthesis and degradation. We also examined whether inhibition of Atrolnc-1 ameliorates muscle wasting in mice with CKD. Results We documented that Atrolnc-1 expression is continuously increased in muscles of mice with fasting (5.4 fold), cancer (2.0 fold), or CKD (5.1 fold). We found that depressed insulin signalling stimulates the transcription factor C/EBP-α binding to the promoter of Atrolnc-1 and promotes the expression of Atrolnc-1. In cultured C2C12 myotubes, overexpression of Atrolnc-1 increases protein degradation (0.45±0.03 vs. 0.64±0.02, *p<0.05); Atrolnc-1 knockdown significantly reduces the rate of protein degradation stimulated by serum depletion (0.61±0.03 vs. 0.47±0.02, *p<0.05). Using mass spectrometry and a lncRNA pull-down assay, we identified that Atrolnc-1 interacts with A20 binding inhibitor of NF-κB-1 (ABIN-1) . The interaction impairs function, resulting in enhanced NF-κB activity plus MuRF-1 transcription. This response is counteracted by CRISPR/dCas9 mediated overexpression. In muscles from normal mice, overexpression of Atrolnc-1 stimulates a 2.7-fold increase in MuRF-1 expression leading to myofibers atrophy. In contrast, Atrolnc-1 knockdown attenuates muscle wasting by 42% in mice with CKD via suppression of NF-κB activity and MuRF-1 expression. Conclusions Our findings provide evidence that lncRNAs initiates the pathophysiological process of muscle wasting. The interaction between Atrolnc-1 and NF-κB signalling modulates muscle mass and proteolysis in CKD and perhaps other catabolic conditions.
Introduction
Muscle wasting is defined as a decrease in the mass of skeletal muscle, an important index for prognosis of chronic diseases. 1 For example, cancer or chronic kidney disease (CKD) patients associated with muscle wasting usually have increased risks of morbidity and mortality. 2 Muscle wasting in CKD or other catabolic conditions is a complex process that occurs as a consequence of impaired IGF-1/insulin signalling, metabolic stress, elevated glucocorticoids, and inflammation. [3] [4] [5] Although significant progress has been made towards understanding muscle protein loss, the behind molecules and cellular mechanisms are still being discovered.
Inflammation has emerged as a critical biological event leading to muscle wasting. Many proinflammatory cytokines such as tumour necrosis factor-α, tumour necrosis factorlike weak inducer of apoptosis, IL-6, and interferon-α reportedly promote proteolysis in muscle. [6] [7] [8] As a key transcription factor mediating inflammatory responses, NF-κB positively regulates muscle protein degradation under various catabolic conditions. 9,10 NF-κB consistently promotes the expression of ubiquitin E3 ligase MuRF-1 to increase muscle proteolysis via the ubiquitin-proteasome system. [11] [12] [13] In cytoplasm, NF-κB binds with its repressor IκB to form an inactive complex. Phosphorylation of IκB leads to its ubiquitination and proteasomal degradation, 14 then NF-κB is freed to enter the nucleus where it can promote the expression of specific gene such as MuRF-1. However, there are several proteins that can inhibit IκB degradation in cytoplasm. Among them, the A20 binding inhibitor of NF-κB-1 (ABIN-1) interacts with A20 and polyubiquitinated NEMO to inhibit IκB degradation and NF-κB activation. 15 Therefore, ABIN-1 functions as an endogenous NF-κB inhibitor to brake NF-κB signalling. 16, 17 Long noncoding RNAs (lncRNAs) are defined as >200 nucleotides RNAs that lack protein-coding potential. 18, 19 Emerging evidences have shown lncRNAs play roles in diverse cellular processes ranging from chromatin modification, RNA stability, to translational control. 20, 21 For example, they can provide scaffolds for protein interactions to regulate signalling pathways involving cell cycle, proliferation, apoptosis, and DNA damage repair. They can also act as transcriptional regulators by interacting with and organizing histone writers, readers, and modifiers. 20, 22 Importantly, aberrant expressions of lncRNAs are associated with diverse pathologies including cancer, cardiac, and muscle diseases. 23, 24 Although mechanisms underlying the broad functions of lncRNAs are rapidly emerging, few studies provided a comprehensive insight of lncRNAs in regulating skeletal muscle proteolysis.
In the current study, we were dedicated to discovering cachexia related lncRNAs and defined their functions in muscle undergoing atrophy. We identified a lncRNA, 1110038 B12Rik was consistently up-regulated in muscles from various mouse models of muscle wasting. Because overexpression of this lncRNA stimulated the expression of MuRF-1 and muscle atrophy, we renamed it as Atrophy-related long noncoding RNA-1 (Atrolnc-1). We uncovered that Atrolnc-1 interacted with ABIN-1, resulting in enhanced NF-κB activity and MuRF-1 expression. These results add a new layer of complexity to MuRF-1 regulation and expand on the spectrum of transcriptional regulation of proteolysis during muscle wasting.
Methods

Mouse strains and chronic kidney disease model
Male C57BL/6 mice (12-week-old) were housed with 12 h light/dark cycles, and all animal procedures were approved in Baylor College of Medicine's Institutional Animal Care and Use Committee. The CKD model was created using subtotal nephrectomy as previously described. 4, 5 Three weeks after subtotal nephrectomy, CKD mice and sham controls underwent intermuscular AAV1 injection into tibialis anterior (TA) muscle and were pair-fed for 3 weeks. For pair-feeding, the amount of chow eaten by CKD mouse is fed to the sham-control mouse, this sequence is repeated for the duration of the experiment. For AAV1 injection, 20 μL of AAV1 (1 × 10 11 g.c) carrying shRNA-scramble (control AAV1), AAV1-Atrolnc-1, or AAV1-shAtrolnc-1 were injected into TA muscles.
Cell culture
The C2C12 mouse myoblasts (ATCC; Manassas, VA, USA) were routinely cultured at 37°C/5% CO 2 in Dulbecco's modified Eagles' medium supplemented with 10% foetal bovine serum (Corning Cellgro, Manassas, VA, USA) and 1% penicillin/streptomycin. For overexpression ABIN-1 in myoblasts, cells were transduced using CRISPR/dCas9 mediated synergistic activation mediator transcription activation system (Cat# sc-425441-LAC, Santa Cruz Biotechnology, Santa Cruz, CA, USA) following the manufactory instruction. For differentiating myotubes, C2C12 myoblasts were incubated with 2% horse serum (American Type Culture Collection) for at least 72 h. We transfected 1 × 10 11 g.c. AAV1 into C2C12 myotubes for 48 h and measured transfection efficiency using real-time quantitative PCR.
RT 2 profiler PCR array analysis
Total RNA was reverse transcribed to cDNA using the First Strand cDNA Kits (Qiagen Sciences, Germantown, MD, USA 
Statistical analysis
Results are presented as mean ± SEM. For experiments comparing two groups, we analysed results by two-tail unpaired Student's t-tests. When more than two groups were compared, two-way ANOVA followed by Newman-Keul's test were used to analyse the differences between the two interested groups. Differences were considered statistically significant at P < 0.05 (*). For other details of techniques and procedures, please see Supplementary Methods.
Results
Characterization of a signature lncRNA in skeletal muscles of catabolic conditions
To identify whether lncRNAs are differentially expressed in muscle wasting, we performed a PCR based lncRNA array (RT 2 lncRNA PCR Array) analysis in quadriceps muscles from three mouse models of catabolic conditions including CKD, starvation (STV), and cancer. We found that several lncRNAs were differentially expressed in muscles of mice with catabolic conditions ( Figure 1A ). We further identified that the expression of eight lncRNAs were simultaneously elevated in atrophying muscles from the three mouse catabolic models, among which 1110038 B12Rik was the most robustly increased lncRNA; meanwhile, the expression of nine lncRNAs were downregulated in muscles from the three catabolic models ( Figure 1B) . Using real-time quantitive PCR, we confirmed that 1110038B12Rik was abundantly expressed in skeletal muscle and its expression was markedly increased in atrophying muscles caused by CKD, STV, and cancer (Figure 1C) . Because 1110038 B12Rik increases in response to muscle atrophy, we named it as Atrolnc-1. The variants of Atrolnc-1 and their expressions in tissues of mice are illustrated in Figure S1 .
Insulin/IGF-1 signalling regulates Atrolnc-1 expression
Because CKD or STV is usually associated with depressed insulin signalling, 3, 4 we hypothesize that insulin or IGF-1 signalling may regulate Atrolnc-1 expression in muscles. We first examined how insulin influences the expression of Atrolnc-1 in serum-starved C2C12 myotubes with or without insulin. As shown in Figure 2A , Atrolnc-1 expression was significantly increased by serum depletion for 24 h, while addition of insulin or IGF-1 eliminated the level of Atrolnc-1 stimulated by serum depletion. Next, we ascertained the mechanism by which insulin suppresses Atrolnc-1 expression. By analysing the promoter region of Atrolnc-1(~2000 BP from transcript site), we found that there are many binding sites for transcription factor C/EBP-α ( Figure 2B ). This stimulated us to investigate if C/EBP-α promotes the expression of Atrolnc-1. 25 We transfected a plasmid containing the Atrolnc-1 promoter following luciferase reporter (Luc-Atrolnc-1) into C2C12 myoblasts ( Figure 2C ), after 24 h, cells were treated with serum depletion or C/EBP-α overexpression. As expected, serum depletion or overexpression of C/EBP-α strongly stimulated Atrolnc-1 promoter activity in C2C12 cells. We then performed a chromatin immunoprecipitation assay to confirm that C/EBP-α is associated with the promoter regions of Atrolnc-1. As shown in Figure 2D , serumdepletion enriched the promotor DNA fragments containing C/EBP-α binding sites in the immune precipitates pulled down by anti-C/EBP-α antibody. Notably, adding insulin (2 μg/mL) decreased the amount of promotor DNA fragments in immune precipitates, indicating that insulin blocked C/EBP-α binding to the promoter of Atrolnc-1 ( Figure 2E ). These results suggest that depressed insulin signalling occurring in CKD or STV mice stimulates C/EBP-α to promote Atrolnc-1 expression in muscles.
Atrolnc-1 regulates protein degradation in muscle cells
To ascertain the function of Atrolnc-1 in the regulation of muscle metabolism, we constructed two AAV1 (Adeno- Graphic presentation (right panel) of the diameter of myotubes calculated from three independent experiments (mean ± SEM, **P < 0.01). (E) C2C12 myotubes with or without Atrolnc-1 overexpression were treated with a proteasomal inhibitor, lactacystin (Lac). Atrolnc-1 overexpression-stimulated proteolysis was largely suppressed by lactacystin (mean ± SEM, n = 6, *P < 0.05). (F) qRT-PCR result shows Atrolnc-1 mRNA levels were reduced by four different short hairpin RNAs (shRNAs) against Atrolnc-1. (G) Agarose gel electrophoresis and the graph (low panel) demonstrated that the Atrolnc-1 mRNA level was reduced by~90% in C2C12 myotubes transfected with AAV1-shAtrolnc-1. (H) The rate of protein synthesis after the knockdown of Atrolnc-1 in C2C12 myotubes (mean ± SEM; n = 6). (I) The rate of protein degradation after the knockdown of Atrolnc-1 in C2C12 myotubes cultured with (left) or without (right) serum. At 48 h after transfection, myotubes with or without Atrolnc-1 knockdown were switched to serum-free (SF) medium for 36 h. The rates of proteolysis were calculated from the linear slopes between 24 and 36 h (mean ± SEM, n = 6 per group, *P < 0.05). (J) The level of p-Akt stays unchanged in myotubes with Atrolnc-1 knockdown when treated with serum depletion (SF). associated virus isotype 1, which has high affinity with skeletal muscle cell) carrying Atrolnc-1 cDNA or shRNA for overexpression or knockdown of Atrolnc-1, respectively. To examine how Atrolnc-1 overexpression influences protein metabolism, C2C12 myotubes were transfected with AAV1 carried Atrolnc-1 cDNA for 48 h, and there was a 3-fold increase in Atrolnc-1 RNA compared with cells transfected with control AAV1 (Figure 3A) . We found that overexpression of Atrolnc-1 did not change the rate of the protein synthesis ( Figure 3B ), but significantly increased the rate of protein degradation in myotubes compared with the results from myotubes transfected with control AAV1 (Figure 3C ). Concomitant with these results, Atrolnc-1 overexpression caused a decrease in the diameter of the myotubes ( Figure 3D ). The increase in overall protein degradation is a result of activation of proteasomal proteolysis because lactacystin (proteasomal inhibitor, 8 μM) significantly suppressed the rate of protein degradation stimulated by Atrolnc-1 overexpression ( Figure 3E ).
To construct AAV1-shAtrolnc, we tested the abilities of four different short hairpin RNAs (shRNAs) to knockdown Atrolnc-1. Two of oligonucleotides (No.1 and No.4, targeting exon5 and exon2, respectively) have the most efficiency at knockdown of Atrolnc-1 ( Figure 3F ). When AAV1 carried No.1 shRNA transfected C2C12 myotubes for 48 h, it efficiently reduced the levels of Atrolnc-1 RNA compared with the myotubes transfected with control shRNA ( Figure 3G ). Following the knockdown of Atrolnc-1, the rate of protein synthesis was not significantly affected ( Figure 3H ). We also found the protein degradation was not influenced, however, when the myotubes were treated with serum depletion, the rate of protein degradation was significantly suppressed by knockdown of Atrolnc-1 ( Figure. 3I ). Of notice, Atrolnc-1 knockdown did not change the level of p-Akt in C2C12 myotubes after cultured with serum free medium ( Figure 3J ). These results indicated that Atrolnc-1 stimulates muscle protein degradation.
Atrolnc-1 enhances the expression of ubiquitin E3 ligase MuRF-1 in muscle cells
To investigate the mechanism by which Atrolnc-1 stimulates muscle proteolysis, we profiled gene expressions using the 'Myogenesis & Myopathy PCR Array' in C2C12 myotubes. 26 Firstly, we examined the expression of these genes in myotubes with Atrolnc-1 knockdown, and found 3 genes were upregulated while 11 genes were downregulated in response to Atrolnc-1 knockdown ( Figure 4A ). Among the downregulated genes, MuRF-1, a major ubiquitin E3 ligase mediating muscle proteolysis was significantly reduced. We also confirmed downregulation of MuRF-1 by western blot, and found a~2-fold decrease of MuRF-1 protein in myotubes with Atrolnc-1 knockdown ( Figure 4B ). Next, we performed the same PCR Array in myotubes with Atrolnc-1 overexpression. More than 20% of the tested genes were upregulated, including MuRF-1 ( Figure 4C) . Using western blot, we confirmed that Atrolnc-1 overexpression significantly stimulated the expression of MuRF-1 in C2C12 myotubes ( Figure 4D ). Of notice, we found that the expression of Atrolnc-1 in myotubes was quickly increased in response to serum depletion (<6 h), much earlier than the induction of MuRF-1-( Figure 4E ), indicating Atrolnc-1 may play a causal role to induce MuRF-1 expression.
Because these results indicate that Atrolnc-1 regulates MuRF-1 expression at transcriptional level, we ascertained signalling pathways involved in the regulation of MuRF-1. By using KEGG pathway enrichment analysis, we found that NF-κB signalling was one of the mostly enriched pathways in response to Atrolnc-1 overexpression or knockdown (Figure 4F) . To confirm that Atrolnc-1 targets NF-κB signalling to stimulate MuRF-1 expressions, we studied the nuclear trafficking of NF-κB (p65) in C2C12 myotubes with overexpression of Atrolnc-1. Using western blotting, we detected that there was a remarkable increase in p65 in nuclear fraction of C2C12 cells after overexpression of Atrolnc-1 for 48 h (Figure 4G) . A NF-κB activity assay further confirmed that overexpression of Atrolnc-1 activates NF-κB signalling in C2C12 myotubes ( Figure 4H ). These results indicate that Atrolnc-1 can promote NF-κB activity in muscle cells.
Atrolnc-1 interacts with ABIN-1 promoting NF-κB-mediated MuRF-1 transcription
To understand how Atrolnc-1 enhances NF-κB activity, we performed RNA in situ hybridization to study the cellular distribution of Atrolnc-1 in C2C12 cells. Atrolnc-1 RNA was located in both cytoplasm and nucleus ( Figure 5A ), suggesting its multiple potential role in gene regulation. Because lncRNAs involved in gene regulation often function via binding to a specific protein(s) in cytoplasm or in nucleus, 22, 27 we then performed an RNA pull-down assay using cytoplasm or nuclear extracts of C2C12 myotubes to identify the proteins that interact with Atrolnc-1. Compared with an antisense, control probe, biotin-labelled full-length Atrolnc-1 precipitated with many cytoplasm proteins shown in SDS-PAGE gel staining with coomassie blue, while few proteins were pulled-down by biotin-Atrolnc-1 probe from nuclear extract ( Figure 5B) . The gels were then analysed with mass spectrometry, and we identified cytoplasmic proteins potentially interacted with Atrolnc-1 ( Figure 5C and Figure S2 ). One of them was ABIN-1, a protein reportedly inhibiting NF-κB signalling. 17 We confirmed the specificity of interaction between ABIN-1 and Atrolnc-1 by immunoblotting using an antibody against ABIN-1. Among proteins pulled-down by biotin-labelled Atrolnc-1, we detected a 72 kD protein that corresponds to ABIN-1 ( Figure 5D left panel) . This interaction also happens in vivo, because RNA pull-down assay using cytoplasmic extraction from the mouse TA muscles also indicated that Atrolnc-1 associated with ABIN-1 ( Figure 5D , right panel). To further evaluate this interaction in vivo, we used anti-ABIN-1 antibody to reciprocally pull-down Atrolnc-1 in mouse TA muscle lysates, followed by a RT-PCR to quantify Atrolnc-1 in the immunoprecipitates. The experiment revealed that Atrolnc-1 is significantly enriched in the precipitate pulled-down by anti-ABIN-1 antibody but not in the precipitate pulled-down by normal IgG, the control antibody. Notably, we observed an increase of interaction between Atrolnc-1 and ABIN-1 in the muscle from mice with CKD, indicating that CKD can stimulate the interaction of Atrolnc-1 with ABIN-1 ( Figure 5E ). Because ABIN-1 is known as a NF-κB inhibitor, the interaction with Atrolnc-1 could interfere with its inhibitory function on NF-κB signalling. To test this hypothesis, we generated a stable C2C12 cell line for overexpression of ABIN-1 using CRISPR/dCas9 mediated synergistic activation mediator transcription activation system (Santa Cruz Biotechnology). We initially validated that ABIN-1 protein level was 2.6-fold increase in the transduced C2C12 cells ( Figure 5F ). When these transduced C2C12 cells were overexpressed with Atrolnc-1, the NF-κB activity was not significantly increased compared with the result from non-transduced, control cells also with Atrolnc-1 overexpression ( Figure 5G ). These results suggested that ABIN-1 overexpression can overcome NF-κB activation that was stimulated by Atrolnc-1. Concomitant with these changes, MuRF-1 expression was also suppressed by ABIN-1 overexpression despite the upregulation of Atrolnc-1 ( Figure 5H ). Based on these observations, we proposed that Atrolnc-1 impedes the inhibitory ability of ABIN-1, resulting in enhanced NF-κB activity and MuRF-1 transcription.
Overexpression of Atrolnc-1 causes myofibers atrophy in mice
Because overexpression of Atrolnc-1 stimulates protein degradation in C2C12 myotubes, we next examine whether overexpression of Atrolnc-1 in muscle can cause myofiber atrophy in vivo. We first validated the transfection efficiency of AAV1 in skeletal muscles. After 14 days of AAV1-GFP injection in TA muscle, we detected more than 80% of myofibers expressed GFP ( Figure 6A ). We then injected AAV1-Atrolnc-1 into TA muscle of normal C57BL/6 mice, there was a remarkable increase of Atrolnc-1 RNA compared with muscles injected with control AAV1 (Figure 6B ). The overexpression of Atrolnc-1 is confirmed by in situ hybridization in TA muscle ( Figure 6C ). To investigate if the overexpression of Atrolnc-1 causes the muscle fibre atrophy, we examined the cross-sectional area (CSA) of myofibers injected with either AAV1-control or AAV1-Atrolnc-1. Atrolnc-1 overexpression in myofiber resulted in a~25% decrease in fibre CSAs compared with the results from myofibers injected with control AAV1-shRNA ( Figure 6D , up-panel). This result was confirmed by the leftward shifting in the distribution of CSAs in myofibers with Atrolnc-1 overexpression ( Figure 6D, low-panel) . We also detected an increase in MuRF-1 expressions compared with results from muscles that were injected with AAV1-control ( Figure 6E and 6F). Thus, Atrolnc-1 overexpression sufficiently causes myofiber atrophy even in normal mice, highlighting its catabolic effects in muscle protein metabolism. CKD. This possibility was tested by using AAV1-mediated gene knockdown in mice with CKD. As shown in Figure 7A , AAV1-shAtrolnc-1 was injected into TA muscles of mice 3 weeks after subtotal nephrectomy. The mice were then paired-fed for 3 weeks before TA muscles were examined. The RNA level of Atrolnc-1 was reduced as much as 76% compared with the results from CKD mice injected with control AAV1 ( Figure 7B ). In mice with CKD, the ratio of TA muscle weight to tibia bone length was remarkably decreased; in contrast, this index of muscle atrophy was significantly improved in CKD mice treated with AAV1-shAtrolnc-1 ( Figure 7C ), indicating inhibition of Atrolnc-1 prevents skeletal muscle mass loss in mice despite CKD. This improvement was confirmed by an increase in CSA of the myofibers (Figure 7d , up-panel) and a rightward shifting in the distribution of myofiber sizes in TA muscles ( Figure 7D , low-panel). Concomitant with these results, the expression of MuRF-1 significantly decreased in TA muscles of CKD mice with Atrolnc-1 knockdown ( Figure 7E ). Thus, inhibition of Atrolnc-1 prevents muscle wasting in mice with CKD and suppresses MuRF-1 expression.
Discussion
Our current study uncovered a lncRNA, which we named Atrolnc-1, may regulate MuRF-1 expression through an interaction with NF-κB signalling. Specifically, our results suggest that Atrolnc-1 stimulates muscle protein breakdown by increasing the expression of MuRF-1. Moreover, we found that Atrolnc-1 interacts with ABIN-1, an endogenous NF-κB inhibitor. This interaction impairs the inhibitive function of ABIN-1, leading to enhanced NF-κB activity and resulting in increasing MuRF-1 expression and muscle proteolysis (Figure 8 ). Besides providing evidence that Atrolnc-1 is one of the mechanisms to stimulate MuRF-1 expression, we also demonstrate that overexpression of Atrolnc-1 in mouse muscles, even in normal condition, is sufficient to cause MuRF-1 induction and muscle atrophy; conversely, inhibition of Atrolnc-1 blocks the induction of MuRF-1 and accelerated muscle wasting in mice with CKD.
Our results indicate that the expression of Atrolnc-1 increases in several catabolic conditions, including CKD, STV, and cancer. All these conditions are associated with impaired insulin/IGF signaling 3 ; therefore, we tested the possibility that insulin-signalling regulates Atrolnc-1 expression. Indeed, we found that insulin can suppress the transcription of Atrolnc-1 (Figure 2) . We also identified that there are many C/EBPs transcription factors binding sites located in the promoter region of Atrolnc-1 gene and C/EBP-α functionally regulates Atrolnc-1 expression. These results are comparable with the previous reports that insulin-signalling can inhibit CEBPs transcriptional activity, 25, 28 but also highlight a critical role of C/EBP-α in lncRNAs transcription. 29 It has been recognized that the biological activities of lncRNAs are dictated by their localization in the cell. 30 We found that Atrolnc-1 localizes both in cytoplasm and in nucleus. We focused on the function of Atrolnc-1 in the cytoplasm because our proteomics result indicated that Atrolnc-1 predominately interacted with cytoplasmic proteins (Figure 5) . Many lncRNA-mediated mechanisms of gene regulation have been identified in the cytoplasm through modulating mRNA stability, regulating mRNA translation, serving as competing endogenous RNAs, and mediating protein modifications. 20, 31 Recently, several lncRNAs have been identified to modulate the function of cytoplasmic proteins by interfering with their protein-protein interaction, suggesting that the interplay between lncRNAs and cytoplasm proteins constitutes an integral aspect of both their biological activities. For example, lincRNA-p21 reportedly binds to HIF-1α under hypoxia condition. This binding blocks the interaction between HIF-α and von Hippel-Lindau tumour suppressor (VHL) protein as a result of promoting HIF-1α mediated glycolytic response. 32 Similarity, we also found Atrolnc-1 binding with ABIN-1, and this interaction inhibited ABIN-1 activity and leaded to NF-κB activation. However, the precision mechanism by which Atrolnc-1 modifies ABIN-1 needs to be unravelled in further studies. Although we have focused on the function of Atrolnc-1 in the cytoplasm in this study, the results cannot exclude the possibility that Atrolnc-1 could regulate genes expression in the nucleus because a single lncRNA can have multiple functions. 33, 34 Our future work will identify the equivalent lncRNA in muscle from human subjects. It may not be a practical approach using evolutional history to predict a function of lncRNA in different species because the current comparative genomic tools cannot easily detect homology among lncRNAs from different species. 35, 36 Therefore, it remains a challenge to identify a human 'homolog' of Atrolnc-1, which has a similar structure or function similar to mouse Atrolnc-1. With this consideration, we plan to use anti-ABIN-1 antibody to reciprocally pull-down the lncRNAs, which associated with ABIN-1 in muscles from human samples. By using RNAsequence techniques, we will identify the lncRNAs, which might modulate ABIN-1 function and examine their functions in regulating of muscle protein turnover. Considering thousands of uncharacterized lncRNAs that could have important physiological functions, our study provides a practical and efficient approach for the identification and characterization of functional lncRNAs in the pathophysiological process of muscle diseases.
In conclusion, we demonstrate that Atrolnc-1 interacts with ABIN-1, promoting the activation of NF-κB and resulting in the increase of MuRF-1 transcriptional output in muscle. Inhibition of Atrolnc-1 in atrophying muscles suppresses MuRF-1 expression and ameliorating muscle wasting. The results of our study also provide further evidence for an important regulatory crosstalk between lncRNAs and NF-κB signaling that could have broader relevance beyond the pathogenesis of muscle diseases.
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